CLINICAL_TRIALS
trial_result
· 2012-05-01
Clinical Trial Update: Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration [Phase 1]
Summary
Phase 1 trial of intravitreal LFG316 in patients with age-related macular degeneration has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Age-related Macular Degeneration | Phase 1 | Status: COMPLETED